Best Life Sciences Companies in South Holland, Netherlands

Provider of TCR T-cell therapeutics for the treatment of cancer. The company uses the adoptive T cell therapies for treating pan-cancer. The company pipeline product includes MAGE-C2/HLA-A2 TCR and epigenetic drugs which can be used in the treatment of melanoma and head-and-neck carcinoma. The company also offers Pan-Cancer T’s platforms which include a dose-escalation of TCR T cells.

Funding rounds

• Dec 2025Series A$5.8M
• Dec 2025Conventional Debt$5.8M
• Jul 2024Seed$4.6M
• Oct 2021Seed—

Founders & team

Reno DebetsFounder

Investors

Swanbridge Capital, Van Herk Groep, Health~Holland, Thuja Capital, InnovationQuarter, Erasmus MC

Tech stack

Animate.CssComplianzDiviGoogle Font ApiJqueryJquery Migrate

Developer of small molecule based therapeutics for the treatment of rare metabolic disorders. It has developed products for patients suffering from lysosomal storage disorders (LSDs) and LSD-related diseases. The compounds interfere with the metabolism of glycolipids that is disturbed in these patients.

Funding rounds

• May 2025Series B$146M
• Feb 2020Series A$27.5M
• Jul 2018Seed—

Founders & team

Stefano PortolanoCEO

Investors

Forbion, BioGeneration Ventures, BioMedPartners, Jeito, Seroba Lifesciences, Pictet Group

Tech stack

FancyboxFlickityGoogle AnalyticsGoogle Font ApiGoogle Tag ManagerHsts

{}

Funding rounds

• Jun 2025Series B$17.2M
• Feb 2023Series A$7.2M
• 2022Grant (prize money)$2.8M
• Jan 2022Grant (prize money)$2.8M

Founders & team

Paul Den BiggelaarCo-Founder & CEOPeter PaassenCo-Founder & COO

Investors

Europa, UNIIQ, EIC Fund, GrayBella Capital, UCEA, InnovationQuarter

DAB is a technology solutions provider for accelerated fermentation. It enables the production of chemicals, materials, and fuel from renewable feedstock. It also provides solutions for fermentations with a water-insoluble product.

Funding rounds

• Oct 2025Series A—
• May 2019Series A$2.2M

Founders & team

Kirsten Herben-SteinbuschFounderSef HeijnenCo-Founder

Investors

InnovationQuarter, FORWARD.one, Navus Ventures, Capricorn Partners, YES!Delft, Delft Enterprises

Tech stack

Amazon SesAmazon Web ServicesCore-JsEmotionGatsbyGoogle Analytics

Developer of RNA modulating therapies for genetic neurological diseases. The company uses VICOMER antisense oligonucleotide platform to design RNA modulating therapeutics to address specific genetic defects such as Rett syndrome, Alzheimer’s disease, Huntington disease, and more. The company's lead candidate is VO659 for multiple polyglutamine disorders, spinocerebellar ataxia type 3 and type 1 and Huntington’s disease.

Funding rounds

• Jun 2024Series B$12.3M
• Jan 2024Series B$60M
• Jul 2020Series A$31M

Founders & team

Judith Van DeutekomScientific Co-Founder and AdvisorJosh Mandel-BrehmFounder and Board MemberGail MandelCo-Founder

Investors

Seroba Lifesciences, Kurma Partners, Ackermans & van Haaren, Droia Ventures, EQT, Eurazeo

Tech stack

AstraCore-JsDocusignElementorGoogle AnalyticsGoogle Font Api

Provider of chemoproteomics solutions for protein design and development. The platform enables researchers to design proteins using predictive algorithms and AI design suggestions. It also offers 3D structure prediction, optimizing thermostability and codon expression.

Funding rounds

• Nov 2024Series B$73M
• Nov 2023Series A$24M
• Nov 2022Seed$5.7M

Founders & team

Stef GriekenCo-Founder & CEOJelle PrinsCo-Founder

Investors

IVP, Index Ventures, Kindred Capital, Next Sequence, Sir Nelson Capital

Tech stack

Apple Icloud MailCloudflareCloudflare Bot ManagementFramer SitesGoogle AnalyticsGoogle Font Api

Developer of medical device to alleviate tremors and enhancing voluntary movement. The flagship product the STIL Orthosis that features specialized dampers that suppress tremors, allowing individuals to perform daily activities for the treatment of tremor disorders.

Funding rounds

• May 2025Seed$2.3M

Founders & team

IJsbrand LangeCo-Founder & CEO

Investors

Rabobank, Health Innovations, European Innovation Council

Tech stack

CloudflareCloudflare Bot ManagementCookie ScriptCore-JsGoogle AnalyticsGoogle Tag Manager

Developer of treatments for chronic wounds. It develops products to eliminate biofilms and infections. It offers an application process suitable for various healthcare settings, designed to address the removal of infected tissue, facilitating wound bed preparation. It helps users to improve the treatment experience for both patients and healthcare providers.

Funding rounds

• Nov 2024PE—
• May 2023PE$10.8M

Founders & team

Alberto CogoCo-FounderCarlo BignozziCo-FounderBert QuintCo-Founder & CEO

Investors

TVM Capital Healthcare

Tech stack

Apache Http ServerApple Icloud MailCloudflareCloudflare Bot ManagementContact Form 7Core-Js

Kaminari Medical is developing a diagnostic solution for vulnerable plaque in the coronary arteries. The company has developed the ultrasound (ivus) and photoacoustic (pa) imaging that can provide information about plaque location and composition.

Funding rounds

• Oct 2024Series A$4.2M
• Oct 2024Conventional Debt$1.6M
• Dec 2019Grant (prize money)—

Founders & team

Jeroen KoddeCEO

Investors

EIT Health, Graduate Ventures, NLC, Libertatis Ergo Holding, Demcon, Rijksdienst voor Ondernemend Nederland

VarmX, a spin-out company from the Leiden University Medical Center, is focussed on development and manufacturing of therapeutic proteins to restore blood clotting in bleeding patients. Its lead product PseudoXa is a modified recombinant human coagulation factor X and is being developed to restore blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. DOACS are taken by patients for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs.

Funding rounds

• May 2023Series B$32.3M
• Sep 2022Grant (prize money)$2.5M
• Oct 2021Grant (prize money)—
• 2021Grant (prize money)$56.5K

Founders & team

Pieter ReitsmaFounder

Investors

Europa, Sound Bioventures, European Innovation Council, EQT, Lundbeck Foundation, Ysios Capital

Developer of Intraocular lenses with shifting optical elements. It offers Lumina lens, an accommodative intraocular lens that can restore vision and accommodation. It uses spring like haptics to allow movement perpendicular to the optical axis, enhancing focal change and providing clear vision without glasses for patients with cataractand presbyopia.

Funding rounds

• Jan 2024Series A$48.1M

Founders & team

Michael RombachFounder & CTOPeter TaalCEO

Investors

MSC, Particon

Micreos develops targeted antibacterial products to replace antibiotics. The company provides Micreos endolysin technology that can kill unwanted bacteria including antibiotic-resistant strains while leaving the beneficial bacteria intact. The company is also involved in the development of Micreos' Staphefekt SA.100 enzyme (endolysin), which can kill Staphylococcus aureus and MRSA. It is also suitable for routine maintenance therapy, for people with skin conditions with an infectious component, such as acne, eczema, psoriasis, and rosacea. The compnay products are FDA-approved.

Funding rounds

• Oct 2022Series D$24.6M
• Dec 2021Grant (prize money)$56.6K
• Sep 2021Series D$37.3M
• Nov 2019Grant (prize money)$2.8M

Founders & team

Mark OfferhausCEO

Investors

EIC Fund, Altria, Oost NL, Government of the Netherlands, Europa, ScaleUpNation